## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.92 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.89)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Who Owns Zimmer Biomet? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260103T120844 | Neutral | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a medical technology company focused on musculoskeletal healthcare. This article details the company's top shareholders, predominantly large institutional investors, and analyzes recent insider trading activity. The analysis suggests a stable institutional shareholder base with varied perspectives on valuation among active managers, and modest insider transaction impact.

**2. Titanium & Titanium Alloys Dental Implants Market is expected**
- Source: openPR.com | 20260105T070956 | Bullish | Relevance: 98%
- The global Titanium & Titanium Alloys Dental Implants Market, valued at US$ 5.86 billion in 2023, is projected to reach US$ 12.33 billion by 2031, with a CAGR of 9.8% from 2024-2031. This growth is driven by the biocompatibility, strength, and corrosion resistance of titanium implants, alongside increasing dental disorders, an aging population, and rising awareness of advanced implant solutions. Key market players include Institut Straumann AG, Dentsply Sirona, and Zimmer Biomet, with recent developments focusing on advanced alloys, 3D-printing, and strategic acquisitions to enhance market offerings.

**3. Trauma Care Centers Market Is Going to Boom | Stryker**
- Source: openPR.com | 20260105T072041 | Bullish | Relevance: 73%
- The global Trauma Care Centers Market is projected to grow from USD 18.73 billion in 2025 to USD 31.48 billion by 2032, exhibiting a CAGR of 7.7%. This growth is driven by rapid innovation and shifting regional dynamics, with key players including Stryker Corporation, Medtronic plc, and Zimmer Biomet Holdings Inc. The market is segmented by trauma center level, ownership type, trauma type, patient age group, service type, and mode of admission.

**4. US Medical Robotics Market to Grow at 16.2% CAGR, Led by Intuitive**
- Source: openPR.com | 20260105T133825 | Somewhat-Bullish | Relevance: 55%
- The US Medical Robotics Market is projected to grow at a CAGR of 16.2% from US$63.53 million in 2024 to US$286.99 million by 2033. This growth is driven by advancements in AI and machine learning, increasing demand for minimally invasive procedures, and rising FDA clearances. Key market players include Intuitive Surgical, Stryker Corporation, and Medtronic Plc, with surgical robots dominating the product type segment and general surgery leading by application.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $120 | $94 | +28% |
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | up | Outperform |
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +3.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.4B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 10.9 |
| Current P/E | 11.3 |
| YoY Growth | 4.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.8% to 1.6% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 54. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.62% (CS: 60) | Neutral |
| RSI_14 | 53.8 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 0.951x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $92.67
- **Stop Loss:** $88.89 (4.1% risk)
- **Target:** $100.23 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 228
- **Position Value:** $21,128.76
- **Portfolio %:** 21.13%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*